Pharming Group N.V. (PHARM.AS)
EUR 0.8
(-3.32%)
EUR 0.8
(-3.32%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 51.38 Million EUR | 21.4% |
| 2022 | 42.32 Million USD | 55.14% |
| 2021 | 27.28 Million EUR | 28.74% |
| 2020 | 21.19 Million EUR | 30.76% |
| 2019 | 16.2 Million EUR | -18.18% |
| 2018 | 19.8 Million EUR | -9.95% |
| 2017 | 21.99 Million EUR | 16.57% |
| 2016 | 18.86 Million EUR | 6.34% |
| 2015 | 17.74 Million EUR | 8.86% |
| 2014 | 16.29 Million EUR | 147.82% |
| 2013 | 6.57 Million EUR | 136.71% |
| 2012 | 2.77 Million EUR | -67.42% |
| 2011 | 8.52 Million EUR | -28.85% |
| 2010 | 11.98 Million EUR | -25.66% |
| 2009 | 16.12 Million EUR | 5.58% |
| 2008 | 15.27 Million EUR | -10.62% |
| 2007 | 17.08 Million EUR | 41.21% |
| 2006 | 12.1 Million EUR | 165.04% |
| 2005 | 4.56 Million EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 59.19 Million EUR | 5.92% |
| 2024 Q3 | 62.22 Million USD | 5.13% |
| 2024 Q1 | 55.88 Million USD | -1.55% |
| 2023 FY | 51.38 Million EUR | 21.4% |
| 2023 Q4 | 56.76 Million USD | 6.21% |
| 2023 Q3 | 53.43 Million USD | 0.75% |
| 2023 Q2 | 53.04 Million USD | 10.21% |
| 2023 Q1 | 48.12 Million USD | 13.71% |
| 2022 Q4 | 42.32 Million USD | 26.32% |
| 2022 Q2 | 33.92 Million USD | 14.6% |
| 2022 Q3 | 33.5 Million USD | -1.25% |
| 2022 FY | 42.32 Million USD | 55.14% |
| 2022 Q1 | 29.6 Million USD | 22.87% |
| 2021 Q2 | 24.31 Million EUR | 11.93% |
| 2021 FY | 27.28 Million EUR | 28.74% |
| 2021 Q3 | 25.09 Million EUR | 3.2% |
| 2021 Q4 | 24.09 Million EUR | -3.98% |
| 2021 Q1 | 21.72 Million EUR | 2.53% |
| 2020 FY | 21.19 Million EUR | 30.76% |
| 2020 Q1 | 16 Million EUR | -1.24% |
| 2020 Q2 | 18.24 Million EUR | 14.0% |
| 2020 Q3 | 19.23 Million EUR | 5.41% |
| 2020 Q4 | 21.19 Million EUR | 10.18% |
| 2019 Q4 | 16.2 Million EUR | 25.14% |
| 2019 Q3 | 12.94 Million EUR | -10.35% |
| 2019 FY | 16.2 Million EUR | -18.18% |
| 2019 Q2 | 14.44 Million EUR | -5.71% |
| 2019 Q1 | 15.31 Million EUR | -22.65% |
| 2018 Q2 | 26.77 Million EUR | 0.51% |
| 2018 Q3 | 24.34 Million EUR | -9.09% |
| 2018 FY | 19.8 Million EUR | -9.95% |
| 2018 Q4 | 19.8 Million EUR | -18.64% |
| 2018 Q1 | 26.64 Million EUR | 21.14% |
| 2017 Q1 | 20.19 Million EUR | 7.05% |
| 2017 FY | 21.99 Million EUR | 16.57% |
| 2017 Q4 | 21.99 Million EUR | 4.1% |
| 2017 Q3 | 21.12 Million EUR | 5.71% |
| 2017 Q2 | 19.98 Million EUR | -1.04% |
| 2016 FY | 18.86 Million EUR | 6.34% |
| 2016 Q1 | 20.22 Million EUR | 14.01% |
| 2016 Q4 | 18.86 Million EUR | -8.49% |
| 2016 Q2 | 21.53 Million EUR | 6.46% |
| 2016 Q3 | 20.61 Million EUR | -4.26% |
| 2015 Q3 | 18.76 Million EUR | 14.92% |
| 2015 Q1 | 16.13 Million EUR | -1.02% |
| 2015 FY | 17.74 Million EUR | 8.86% |
| 2015 Q2 | 16.32 Million EUR | 1.2% |
| 2015 Q4 | 17.74 Million EUR | -5.44% |
| 2014 Q3 | 11.66 Million EUR | 23.28% |
| 2014 FY | 16.29 Million EUR | 147.82% |
| 2014 Q2 | 9.46 Million EUR | -8.02% |
| 2014 Q4 | 16.29 Million EUR | 39.76% |
| 2014 Q1 | 10.28 Million EUR | 56.37% |
| 2013 Q2 | 2.82 Million EUR | -0.61% |
| 2013 FY | 6.57 Million EUR | 136.71% |
| 2013 Q4 | 6.57 Million EUR | 78.08% |
| 2013 Q3 | 3.69 Million EUR | 30.94% |
| 2013 Q1 | 2.83 Million EUR | 2.13% |
| 2012 Q4 | 2.77 Million EUR | -45.51% |
| 2012 Q1 | 9.98 Million EUR | 17.05% |
| 2012 FY | 2.77 Million EUR | -67.42% |
| 2012 Q3 | 5.09 Million EUR | 0.0% |
| 2011 Q2 | 11.45 Million EUR | -8.77% |
| 2011 Q1 | 12.55 Million EUR | 4.76% |
| 2011 Q3 | 9.34 Million EUR | -18.43% |
| 2011 Q4 | 8.52 Million EUR | -8.73% |
| 2011 FY | 8.52 Million EUR | -28.85% |
| 2010 Q3 | 15.24 Million EUR | 11.67% |
| 2010 FY | 11.98 Million EUR | -25.66% |
| 2010 Q4 | 11.98 Million EUR | -21.38% |
| 2010 Q2 | 13.65 Million EUR | -9.89% |
| 2010 Q1 | 15.15 Million EUR | -6.04% |
| 2009 FY | 16.12 Million EUR | 5.58% |
| 2009 Q4 | 16.12 Million EUR | 0.0% |
| 2008 FY | 15.27 Million EUR | -10.62% |
| 2007 FY | 17.08 Million EUR | 41.21% |
| 2006 FY | 12.1 Million EUR | 165.04% |
| 2005 FY | 4.56 Million EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -23150.131% |
| ABIVAX Société Anonyme | 1.00 EUR | -5138278900.0% |
| Adocia SA | 272 Thousand EUR | -18790.732% |
| Aelis Farma SA | 53 Thousand EUR | -96848.66% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | -2851.338% |
| genOway Société anonyme | 982.75 Thousand EUR | -5128.465% |
| IntegraGen SA | 311.44 Thousand EUR | -16397.979% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -31112.59% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 4734.692% |
| Plant Advanced Technologies SA | 1.22 Million EUR | -4096.01% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 43215.048% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -56364.604% |
| Valbiotis SA | 1 Million EUR | -5012.721% |
| TheraVet SA | 123.34 Thousand EUR | -41558.794% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -5138278900.0% |
| argenx SE | 281.12 Million EUR | 81.723% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | -3977.999% |
| DBV Technologies S.A. | 1.00 USD | -5138278900.0% |
| Galapagos NV | 73.97 Million EUR | 30.543% |
| Genfit S.A. | 4000.00 EUR | -1284469.75% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -5138278900.0% |
| Innate Pharma S.A. | 1.00 EUR | -5138278900.0% |
| Inventiva S.A. | 417 Thousand EUR | -12222.012% |
| MaaT Pharma SA | 190 Thousand EUR | -26943.574% |
| MedinCell S.A. | -6.71 Million EUR | 865.308% |
| Nanobiotix S.A. | 200 Thousand EUR | -25591.395% |
| Onward Medical N.V. | 936 Thousand EUR | -5389.614% |
| Oryzon Genomics S.A. | 6029.00 EUR | -852160.574% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -40042.805% |
| Poxel S.A. | 2.95 Million EUR | -1638.254% |
| GenSight Biologics S.A. | 1.00 EUR | -5138278900.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 95.016% |
| Valneva SE | 44.46 Million EUR | -15.555% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -5138278900.0% |